Top

Journal of Hematology & Oncology

Published in:

Open Access 01-12-2021 | NSCLC | Review

Antibody–drug conjugates in solid tumors: a look into novel targets

Published in: Journal of Hematology & Oncology | Issue 1/2021

Title: Antibody–drug conjugates in solid tumors: a look into novel targets
Publication date: 01-12-2021
Keywords: NSCLC
Solid Tumor
NSCLC
Trastuzumab Deruxtecan
Published in: Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-021-01035-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1/2021

Emerging agents and regimens for AML

Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine

Keynote webinar | Spotlight on antibody–drug conjugates in cancer